Predictors of Treatment Failure with Sofosbuvir/Daclatasvir Regimen for 12 Weeks in Patients with Chronic HCV in Egypt
Ahmed Tawheed, Mohamed El Kassas, Amr El Fouly & Gamal Esmat · International Journal of TROPICAL DISEASE & Health · 2023
Background: Hepatitis C virus HCV infection is one of the main causes of chronic liver disease worldwide, Egypt has the highest national-level HCV prevalence in the world, Sofosbuvir/ Daclatasvir (SOF/DAC) regimen widely used to treat HCV infection in Egypt. Aims: to identify the...
Open access
Research Article
10.9734/ijtdh/2023/v44i11383